http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109232746-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43504 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
filingDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-109232746-B |
titleOfInvention | Fusion polypeptide of ziconotide and TAT peptide |
abstract | The invention provides a fusion polypeptide of ziconotide and TAT peptide. The invention uses the C end of ziconotide to connect with the N end of cell membrane penetrating peptide to obtain fusion peptide, which overcomes the defects of incapable intramuscular injection and the like. The fusion polypeptide can pass through a blood brain barrier, is suitable for intravenous, abdominal or nasal administration modes, is convenient to operate, has small clinical risk, is applied through veins, abdominal or nasal cavities, has long drug effect acting time in vivo, has excellent analgesic effect and small peptide side effect, and is suitable for large-scale clinical application. The fusion polypeptide of the invention has simple preparation, controllable quality of the preparation process and the preparation process, and is suitable for large-scale industrialized production. |
priorityDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.